Event:
The comprehensive group of joint prevention and control mechanism of the State Council formulated and issued the application scheme for covid-19 virus antigen detection (Trial)
Key investment points:
The comprehensive group of the joint prevention and control mechanism of the State Council formulated and issued the application scheme for covid-19 virus antigen detection (Trial), opening up a broad market for covid-19 antigen detection. The National Health Commission announced on the evening of March 1 that the comprehensive group of the joint prevention and control mechanism of the State Council decided to add antigen detection as a supplement on the basis of nucleic acid detection, and organized and formulated the application scheme for covid-19 virus antigen detection (Trial). The scheme stipulates the applicable groups for antigen detection: I. those who go to grass-roots medical and health institutions with respiratory tract, fever and other symptoms within 5 days; II. Isolation and observation personnel, including personnel in home isolation and observation, close connection and secondary close connection, entry isolation and observation, sealing and control area and control area; III Community residents with antigen self-test needs. This opens the door to covid-19 antigen detection in China.
The constantly mutating virus and the complicated international covid-19 epidemic situation have given birth to the covid-19 antigen detection industry. Five VOCs have emerged since covid-19 virus spread. The infectivity of Omicron virus, which swept the world recently, has increased 13 times, but the death rate is only 0.09 times that of delta mutant strain. Based on the trend of virus mutation to low mortality, most countries in the world have adopted an open attitude to deal with the epidemic, which increases the probability of virus transmission and puts great pressure on China’s epidemic prevention and control. In the past month, many provinces and cities in China have been invaded by Omicron mutant, and the nucleic acid detection in the hospital has become increasingly difficult in the face of a large demand. At the same time, the aggregation detection also increases the risk of cross infection. A variety of reasons have led to covid-19 antigen detection to fill the gap of nucleic acid detection in the hospital and reduce the risk of centralized detection.
Retail pharmacies combined with online sales platforms and other channels to improve the accessibility of covid-19 antigen self-test, and the field is expected to usher in rapid growth. Covid-19 virus antigen detection application scheme (Trial Implementation) indicates that if community residents have self-detection needs, they can purchase antigen detection reagents for self-test through retail pharmacies, online sales platforms and other channels. With the “influenza” of covid-19 pneumonia and the gradual opening of the international situation, residents are at greater and greater risk of exposure to the virus. Therefore, covid-19 detection has become a living need. According to the program guidance, covid-19 antigen detection has also been opened at the national level to comprehensively open up channels and improve the accessibility of covid-19 antigen self-test, so as to meet the detection needs of the majority of residents. In conclusion, the field of covid-19 antigen self-test is expected to usher in rapid growth.
Four covid-19 antigen detection kits have passed the registration information change of the food and drug administration, and more covid-19 antigen self-test products are expected to be approved in the future. This means that the reagent kit of Wofu will no longer be used by the professional testing personnel of Wofu Medical Supervision Bureau on December 19, which means that the reagent kit of Wofu Medical Supervision Bureau will no longer be used for the testing of antigen and in the future, The above four manufacturers also became the first batch of “crab eaters” to seize the opportunity. Many Chinese enterprises have covid-19 antigen self-test kits listed in Europe and the United States. With the opening of covid-19 antigen self-test by the state, more covid-19 antigen self-test products are expected to be approved in China in the future.
Companies that focus on the company focus on the following companies: Guangzhou Wondfo Biotech Co.Ltd(300482) \ \, Thalys Medical Technology Group Corporation(603716) , Livzon Pharmaceutical Group Inc(000513) \ Yifeng Pharmacy Chain Co.Ltd(603939) , Dashenlin Pharmaceutical Group Co.Ltd(603233) , China Meheco Group Co.Ltd(600056) , Yunnan Jianzhijia Health-Chain Co.Ltd(605266) , Realcan Pharmaceutical Group Co.Ltd(002589) .
Covid-19 antigen detection is a rigid demand. The State supports covid-19 antigen detection. The performance growth of relevant companies is stable and the recommended rating is maintained.
Risk warning: the risk that the policy support is lower than expected, the risk that the review speed is lower than expected, the risk that the product volume does not meet the expectation, the risk that the product price is controlled by the state, and the risk that the change of epidemic situation in the future is unpredictable. Focus on the risk that the company’s performance is lower than expected.
